Steven Cohen Protagonist Therapeutics, Inc Transaction History
Point72 Asset Management, L.P.
- $36 Billion
- Q2 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 909,734 shares of PTGX stock, worth $40.5 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
909,734
Previous 909,734
-0.0%
Holding current value
$40.5 Million
Previous $31.5 Million
-0.0%
% of portfolio
0.09%
Previous 0.09%
Shares
18 transactions
Others Institutions Holding PTGX
# of Institutions
195Shares Held
58.7MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$260 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$236 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$148 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$145 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.19B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...